Laboratory Monitoring for GLP-1 Receptor Agonists
For patients on GLP-1 receptor agonist therapy, monitor kidney function (eGFR) at baseline and periodically (at least annually, or every 3-6 months if eGFR <60 mL/min/1.73 m²), home glucose levels closely for the first 4 weeks (especially if on insulin or sulfonylureas), and consider monitoring vitamin D, vitamin B12, iron studies, folate, zinc, and thiamine in high-risk patients, though routine thyroid function testing is not required based on current evidence.
Core Laboratory Monitoring
Kidney Function (eGFR)
- Baseline assessment required before initiating therapy 1
- Monitor at least annually in patients with normal kidney function 1
- Increase monitoring frequency to every 3-6 months when eGFR <60 mL/min/1.73 m² 1
- Most GLP-1 RAs require no dose adjustment for CKD, but exenatide should be avoided with eGFR <30 mL/min/1.73 m² and exenatide ER with eGFR <45 mL/min/1.73 m² 1, 2
Glucose Monitoring
- Intensify home glucose monitoring for the first 4 weeks of therapy 3
- This is particularly critical if the patient is on insulin, sulfonylureas, or glinides due to increased hypoglycemia risk 3
- Consider discontinuing sulfonylureas or reducing insulin dose by ~20% when starting GLP-1 RA therapy 3
Micronutrient Monitoring in High-Risk Patients
Recent evidence suggests GLP-1 RAs may predispose to nutritional deficiencies through appetite suppression and altered absorption 4, 5. Consider monitoring the following in patients at increased malnutrition risk:
Vitamin D
- Most common deficiency: 7.5% at 6 months, 13.6% at 12 months 5
- Average intake only 20% of recommendations 5
Iron Studies
- GLP-1 RA users show 26-30% lower ferritin levels compared to other diabetes medications 5
- More than 60% consume below estimated iron requirements 5
Additional Micronutrients to Consider
- Vitamin B12 (cobalamin): Deficits increase over time 5
- Folate 4
- Zinc 4
- Thiamine: Particularly in high-risk patients 4
- Calcium: More than 60% consume below requirements, contributing to lean mass loss 5
Thyroid Function Testing
Routine thyroid function monitoring is NOT required based on current evidence 6. While long-acting GLP-1 RAs carry a black box warning for medullary thyroid cancer risk (based on rodent studies), systematic thyroid function assessment has not been incorporated into major clinical trials 6.
Exception: Advise patients to undergo guideline-recommended eye examinations before starting therapy if not done within the last 12 months, and discuss potential risk of diabetic retinopathy complications with dulaglutide or injectable semaglutide 3.
Clinical Monitoring Beyond Labs
First 4 Weeks
- Close glucose monitoring at home 3
- Assess for gastrointestinal symptoms (nausea, vomiting, diarrhea) 7
- Monitor for signs of pancreatitis (nausea, vomiting, abdominal pain) 7
- Educate on symptoms requiring immediate attention
Ongoing Monitoring
- Body composition assessment using DXA or BIA to track lean mass preservation 4
- Foot care monitoring, especially in patients with diabetic neuropathy 3
- Signs of dehydration (lightheadedness, orthostasis, weakness) 3
Common Pitfalls to Avoid
- Failing to reduce insulin/sulfonylurea doses when initiating GLP-1 RA therapy, leading to hypoglycemia 3
- Not discontinuing DPP-4 inhibitors before starting GLP-1 RAs (they should never be used together) 1
- Overlooking micronutrient deficiencies in patients with significant weight loss or reduced oral intake 4, 5
- Inadequate protein intake (<1.2 g/kg/day) contributing to lean mass loss 4
- Continuing GLP-1 RAs perioperatively without clear guidance on timing (limited data available) 8
Special Populations
Patients with CKD
- No dose adjustment needed for most GLP-1 RAs (dulaglutide, liraglutide, semaglutide) 1, 2
- Monitor eGFR more frequently as kidney function declines 1
Patients on Metformin
- If also on metformin, monitor vitamin B12 after 4 years of metformin therapy 1
Patients at High Malnutrition Risk
- Older adults, sarcopenic obesity, vegetarian/vegan diets, baseline micronutrient inadequacies 4
- Consider comprehensive micronutrient panel at baseline and periodically